{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:46:07Z","timestamp":1792539967103,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bioorg.2023.106507","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T14:53:50Z","timestamp":1680274430000},"page":"106507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Recent advances and future perspectives of noncompetitive proteasome inhibitors"],"prefix":"10.1016","volume":"135","author":[{"given":"Gongruixue","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangxiao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1073\/pnas.74.1.54","article-title":"A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes","volume":"74","author":"Etlinger","year":"1977","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106507_b0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1756-185X.2012.01737.x","article-title":"The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases","volume":"15","author":"Chitra","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"issue":"21","key":"10.1016\/j.bioorg.2023.106507_b0015","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.3390\/ijms222111595","article-title":"Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.bioorg.2023.106507_b0020","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.jmb.2017.05.027","article-title":"Proteasome structure and assembly","volume":"429","author":"Budenholzer","year":"2017","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","article-title":"Regulation of proteasome activity in health and disease","volume":"1843","author":"Schmidt","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Res."},{"key":"10.1016\/j.bioorg.2023.106507_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00073","article-title":"The ubiquitin proteasome system in glia and its role in neurodegenerative diseases","volume":"7","author":"Jansen","year":"2014","journal-title":"Front. Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0035","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/biom10050796","article-title":"Unstructured biology of proteins from ubiquitin-proteasome system: roles in cancer and neurodegenerative diseases","volume":"10","author":"Gadhave","year":"2020","journal-title":"Biomolecules"},{"issue":"92","key":"10.1016\/j.bioorg.2023.106507_b0040","first-page":"S74","article-title":"The immunoproteasome: a novel drug target for autoimmune diseases","volume":"33","author":"Basler","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106507_b0045","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acsinfecdis.9b00216","article-title":"Identification of small molecules disrupting the ubiquitin proteasome system in malaria","volume":"5","author":"Mata-Cantero","year":"2019","journal-title":"ACS Infect. Dis."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106507_b0050","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1021\/acsinfecdis.1c00110","article-title":"High throughput screening to identify selective and nonpeptidomimetic proteasome inhibitors as antimalarials","volume":"7","author":"Mata-Cantero","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106507_b0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1359-6446(03)02647-3","article-title":"Potential for proteasome inhibition in the treatment of cancer","volume":"8","author":"Adams","year":"2003","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","article-title":"Proteasome inhibitors in cancer therapy","volume":"5","author":"Crawford","year":"2011","journal-title":"J. Cell Commun. Signal."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106507_b0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem. Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/ph15050531","article-title":"Covalent inhibition of the human 20S proteasome with homobelactosin C inquired by QM\/MM studies","volume":"15","author":"Serrano-Aparicio","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.bioorg.2023.106507_b0075","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1515\/hsz-2012-0212","article-title":"Covalent and non-covalent reversible proteasome inhibition","volume":"393","author":"Beck","year":"2012","journal-title":"Biol. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14656566.2018.1441287","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"19","author":"Scalzulli","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2023.106507_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111646","article-title":"Immunoproteasome-selective inhibitors: an overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases","volume":"182","author":"Xi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2023.106507_b0095","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2023.106507_b0100","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/eji.202249851","article-title":"Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome","volume":"52","author":"del Rio Oliva","year":"2022","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0105","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10555-017-9705-x","article-title":"Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing","volume":"36","author":"Soave","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2023.106507_b0110","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106507_b0115","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/molecules27072201","article-title":"Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance","volume":"27","author":"Leonardo-Sousa","year":"2022","journal-title":"Molecules"},{"issue":"14","key":"10.1016\/j.bioorg.2023.106507_b0120","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1021\/jm400235r","article-title":"Inhibition of the human proteasome by imidazoline Scaffolds","volume":"56","author":"Azevedo","year":"2013","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0125","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1016\/S1074-5521(00)00115-0","article-title":"Allosteric drugs: thinking outside the active-site box","volume":"7","author":"DeDecker","year":"2000","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/scientificamerican0809-70","article-title":"A new kind of drug target","volume":"301","author":"Wenner","year":"2009","journal-title":"Sci. Am."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2023.106507_b0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drudis.2008.09.011","article-title":"In search of negative allosteric modulators of biological targets","volume":"14","author":"Groebe","year":"2009","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0140","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1535-7163.MCT-08-0735","article-title":"Aminopeptidase inhibition as a targeted treatment strategy in myeloma","volume":"8","author":"Moore","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106507_b0145","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","article-title":"In Vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells","volume":"19","author":"Chauhan","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bioorg.2023.106507_b0150","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1111\/febs.15638","article-title":"Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies","volume":"288","author":"Chen","year":"2021","journal-title":"FEBS J."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106507_b0155","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1016\/j.bmc.2013.01.056","article-title":"Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting","volume":"21","author":"Ciechanover","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106507_b0160","doi-asserted-by":"crossref","DOI":"10.1042\/BST0350012","article-title":"Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy","volume":"35","author":"Goldberg","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106507_b0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrm1336","article-title":"Proteasomes and their kin: proteases in the machine age","volume":"5","author":"Pickart","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrm2630","article-title":"Molecular mechanisms of proteasome assembly","volume":"10","author":"Murata","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annual Review Biochemistry"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q","article-title":"Ubiquitin-mediated proteolysis: biological regulation via destruction","volume":"22","author":"Ciechanover","year":"2000","journal-title":"Bioessays"},{"issue":"13","key":"10.1016\/j.bioorg.2023.106507_b0185","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s00018-004-4129-5","article-title":"Ubiquitin-proteasome system: a field guide to ubiquitylation","volume":"61","author":"Fang","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0014-5793(94)01177-X","article-title":"The 26S proteasome of the yeast Saccharomyces Cerevisiae","volume":"355","author":"Fischer","year":"1994","journal-title":"FEBS Lett."},{"issue":"3\u20134","key":"10.1016\/j.bioorg.2023.106507_b0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0300-9084(01)01241-X","article-title":"20S proteasome biogenesis","volume":"83","author":"Kr\u00fcger","year":"2001","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.bioorg.2023.106507_b0200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jmcb\/mjq030","article-title":"Structure, assembly and homeostatic regulation of the 26S proteasome","volume":"2","author":"Xie","year":"2010","journal-title":"J. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.str.2014.11.017","article-title":"Crystal structure of the human 20S proteasome in complex with carfilzomib","volume":"23","author":"Harshbarger","year":"2015","journal-title":"Structure"},{"issue":"14","key":"10.1016\/j.bioorg.2023.106507_b0210","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1021\/acs.jmedchem.9b00101","article-title":"Proteasome activation as a new therapeutic approach to target proteotoxic disorders","volume":"62","author":"Njomen","year":"2019","journal-title":"J. Med. Chem."},{"issue":"40","key":"10.1016\/j.bioorg.2023.106507_b0215","doi-asserted-by":"crossref","first-page":"25200","DOI":"10.1074\/jbc.272.40.25200","article-title":"The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing","volume":"272","author":"Heinemeyer","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2023.106507_b0220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2017.09.001","article-title":"Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma","volume":"182","author":"Ettari","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0225","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2012.11.004","article-title":"The immunoproteasome in antigen processing and other immunological functions","volume":"25","author":"Basler","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bioorg.2023.106507_b0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2023.106507_b0235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","article-title":"Immunoproteasomes","volume":"109","author":"Ferrington","year":"2012","journal-title":"In progress in molecular biology and translational, Science"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0240","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jlb.56.5.571","article-title":"Role of proteasomes modified by interferon- \u03b3 in antigen processing","volume":"56","author":"Tanaka","year":"1994","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tibs.2013.10.004","article-title":"The unique functions of tissue-specific proteasomes","volume":"39","author":"Kniepert","year":"2014","journal-title":"Trends Biochem. Sci"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0250","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1021\/acs.jmedchem.9b01226","article-title":"The immunoproteasome: an emerging target in cancer and autoimmune and neurological disorders","volume":"63","author":"Zerfas","year":"2020","journal-title":"J. Med. Chem."},{"issue":"5829","key":"10.1016\/j.bioorg.2023.106507_b0255","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8 + T cell development by thymus-specific proteasomes","volume":"316","author":"Murata","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2023.106507_b0260","doi-asserted-by":"crossref","unstructured":"T. Nitta, S. Murata, T. Ueno, K. Tanaka, Y. Takahama, Chapter 3 Thymic microenvironments for T-cell repertoire formation. In Advances in Immunology 99 (2008) 59\u201394.","DOI":"10.1016\/S0065-2776(08)00603-2"},{"key":"10.1016\/j.bioorg.2023.106507_b0265","first-page":"071","article-title":"Recognition and processing of misfolded proteins by PA700, the 19S regulatory complex of the 26S proteasome","volume":"301","author":"Liu","year":"2005","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0270","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and function of the 26S proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0275","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s13238-017-0382-x","article-title":"Reversible phosphorylation of the 26S proteasome","volume":"8","author":"Guo","year":"2017","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0280","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/biom11020228","article-title":"PA28\u03b3: new insights on an ancient proteasome activator","volume":"11","author":"Cascio","year":"2021","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0285","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2010.02.002","article-title":"Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening","volume":"37","author":"Sadre-Bazzaz","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2023.106507_b0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2023.106507_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107526","article-title":"Exploring the proteasome system: a novel concept of proteasome inhibition and regulation","volume":"211","author":"Wang","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbcan.2011.10.003","article-title":"The 26S proteasome complex: an attractive target for cancer therapy","volume":"1825","author":"Frankland-Searby","year":"2012","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"9","key":"10.1016\/j.bioorg.2023.106507_b0305","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1158\/1535-7163.MCT-08-0391","article-title":"Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the P38 mitogen-activated protein kinase pathway","volume":"7","author":"Lioni","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/auto.6.1.10323","article-title":"Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells","volume":"6","author":"Periyasamy-Thandavan","year":"2010","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0315","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/15384047.2019.1702403","article-title":"Harnessing the vulnerabilities of P53 mutants in lung cancer \u2013 focusing on the proteasome: a new trick for an old foe?","volume":"21","author":"Oduah","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106507_b0320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.seminhematol.2012.04.006","article-title":"Biologic impact of proteasome inhibition in multiple myeloma cells\u2014from the aspects of preclinical studies","volume":"49","author":"Hideshima","year":"2012","journal-title":"Semin. Hematol."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0325","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Can. Metastasis Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106507_b0330","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell Mol. Med."},{"issue":"6059","key":"10.1016\/j.bioorg.2023.106507_b0335","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0340","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s43440-021-00238-y","article-title":"JNK Signaling as a target for anticancer therapy","volume":"73","author":"Abdelrahman","year":"2021","journal-title":"Pharmacol. Rep."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0345","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"5468","key":"10.1016\/j.bioorg.2023.106507_b0350","first-page":"1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of P53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science, New Series"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0355","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1747-1028-7-26","article-title":"Therapeutic targeting of cancer cell cycle using proteasome inhibitors","volume":"7","author":"Rastogi","year":"2012","journal-title":"Cell Div."},{"issue":"7619","key":"10.1016\/j.bioorg.2023.106507_b0360","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0365","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1365-2958.2005.05036.x","article-title":"Structure of the Mycobacterium Tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate: Mtb proteasome structure","volume":"59","author":"Hu","year":"2006","journal-title":"Mol. Microbiol."},{"issue":"19","key":"10.1016\/j.bioorg.2023.106507_b0370","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases","volume":"63","author":"Nagle","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106507_b0375","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/molecules25061305","article-title":"Psoralen derivatives as inhibitors of mycobacterium tuberculosis proteasome","volume":"25","author":"Ro\u017eman","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0380","doi-asserted-by":"crossref","first-page":"193","DOI":"10.23736\/S0031-0808.20.04148-8","article-title":"Old and new generation proteasome inhibitors in multiple myeloma","volume":"62","author":"Montefusco","year":"2021","journal-title":"Panminerva Med."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0385","first-page":"171","article-title":"Drug resistance and minimal residual disease in multiple myeloma","volume":"5","author":"Gozzetti","year":"2022","journal-title":"Cancer Drug Resistance"},{"issue":"11","key":"10.1016\/j.bioorg.2023.106507_b0390","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.febslet.2009.03.019","article-title":"The structural basis of allosteric regulation in proteins","volume":"583","author":"Laskowski","year":"2009","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0395","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41467-017-01760-5","article-title":"Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes","volume":"8","author":"Santos","year":"2017","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.bioorg.2023.106507_b0400","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1089\/ars.2013.5816","article-title":"Harnessing proteasome dynamics and allostery in drug design","volume":"21","author":"Gaczynska","year":"2014","journal-title":"Antioxid. Redox Signal."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106507_b0405","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI9826","article-title":"Inhibition of ubiquitin-proteasome pathway-mediated I\u03baB\u03b1 degradation by a naturally occurring antibacterial peptide","volume":"106","author":"Gao","year":"2000","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.bioorg.2023.106507_b0410","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2174\/1381612023395394","article-title":"Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action","volume":"8","author":"Gennaro","year":"2002","journal-title":"Curr. Pharm. Des."},{"issue":"29","key":"10.1016\/j.bioorg.2023.106507_b0415","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1021\/bi034784f","article-title":"Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity","volume":"42","author":"Gaczynska","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2023.106507_b0420","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0076-6879(05)98035-X","article-title":"Characterization of noncompetitive regulators of proteasome activity","volume":"398","author":"Gaczynska","year":"2005","journal-title":"Methods Enzymol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0425","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2008.09.021","article-title":"Molecular basis for proline- and arginine-rich peptide inhibition of proteasome","volume":"384","author":"Anbanandam","year":"2008","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106507_b0430","doi-asserted-by":"crossref","first-page":"H2612","DOI":"10.1152\/ajpheart.2001.281.6.H2612","article-title":"PR-39 and PR-11 Peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I\u03baB\u03b1 degradation","volume":"281","author":"Bao","year":"2001","journal-title":"Am. J. Physiol.-Heart Circulat. Physiol."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106507_b0435","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-2836(05)80133-0","article-title":"Structural studies of HIV-1 tat protein","volume":"247","author":"Bayer","year":"1995","journal-title":"J. Mol. Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106507_b0440","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/bip.21381","article-title":"Potential allosteric modulators of the proteasome activity","volume":"93","author":"Jankowska","year":"2010","journal-title":"Biopolymers"},{"issue":"8","key":"10.1016\/j.bioorg.2023.106507_b0445","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/psc.2642","article-title":"Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome","volume":"20","author":"Witkowska","year":"2014","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.bioorg.2023.106507_b0450","doi-asserted-by":"crossref","unstructured":"M. Imran, S.A Khan, Abida; A.S. Alshrari, M.M. Eltahir Mudawi, M.K. Alshammari, A.A. Harshan, N.A. Alshammari, Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021. Expert Opinion on Therapeutic Patents 32(5) (2022) 591\u2013604.","DOI":"10.1080\/13543776.2022.2045948"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106507_b0455","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/cb300568r","article-title":"Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo","volume":"8","author":"Lansdell","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"26","key":"10.1016\/j.bioorg.2023.106507_b0460","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1021\/bi8005913","article-title":"TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors","volume":"47","author":"Sprangers","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2023.106507_b0465","doi-asserted-by":"crossref","unstructured":"A.M. Ruschak, L.E. Kay, Proteasome allostery as a population shift between interchanging conformers. In: Proceedings of the National Academy of Sciences of the United States of America 2012, 109 (50).","DOI":"10.1073\/pnas.1213640109"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0470","doi-asserted-by":"crossref","first-page":"182","DOI":"10.18295\/squmj.2016.16.02.008","article-title":"Effect of Khat (Catha Edulis) use on the bioavailability, plasma levels and antimalarial activity of chloroquine","volume":"16","author":"Issa","year":"2016","journal-title":"Sultan Qaboos Univ. Med. J."},{"issue":"14","key":"10.1016\/j.bioorg.2023.106507_b0475","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jnci\/djq198","article-title":"Effect of noncompetitive proteasome inhibition on bortezomib resistance","volume":"102","author":"Li","year":"2010","journal-title":"J. Natl Cancer Inst."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0480","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Reviews"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106507_b0485","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/mi.5.3.6","article-title":"The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine","volume":"5","author":"Peng","year":"2005","journal-title":"Mol. Interv."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106507_b0490","first-page":"1205","article-title":"The role of the proteasome in apoptosis induced by anthracycline anticancer agents","volume":"20","author":"Kiyomiya","year":"2002","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2023.106507_b0495","first-page":"1081","article-title":"Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome","volume":"21","author":"Kiyomiya","year":"2002","journal-title":"Int. J. Oncol."},{"issue":"28","key":"10.1016\/j.bioorg.2023.106507_b0500","doi-asserted-by":"crossref","first-page":"16455","DOI":"10.1074\/jbc.271.28.16455","article-title":"The antitumor drug aclacinomycin a, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome","volume":"271","author":"Figueiredo-Pereira","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2023.106507_b0505","doi-asserted-by":"crossref","first-page":"13395","DOI":"10.1074\/jbc.M700498200","article-title":"The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain","volume":"282","author":"Edwards","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0510","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1124\/mol.112.083873","article-title":"Rapamycin allosterically inhibits the proteasome","volume":"84","author":"Osmulski","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106507_b0515","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1039\/C9OB00122K","article-title":"Pipecolic esters as minimized templates for proteasome inhibition","volume":"17","author":"Giletto","year":"2019","journal-title":"Org. Biomol. Chem. Org."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106507_b0520","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bmcl.2011.02.041","article-title":"Synthesis and proteasome inhibition of lithocholic acid derivatives","volume":"21","author":"Dang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106507_b0525","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejmech.2017.11.056","article-title":"Tamoxifen a pioneering drug: an update on the therapeutic potential of tamoxifen derivatives","volume":"143","author":"Shagufta","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106507_b0530","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejmech.2013.11.009","article-title":"A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor","volume":"71","author":"Hasegawa","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106507_b0535","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00253-011-3689-1","article-title":"Biosynthesis and function of gliotoxin in aspergillus fumigatus","volume":"93","author":"Scharf","year":"2012","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106507_b0540","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1074-5521(00)80016-2","article-title":"The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome","volume":"6","author":"Kroll","year":"1999","journal-title":"Chem. Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106507_b0545","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00436-002-0644-1","article-title":"In vitro effects of gliotoxin, a natural proteasome inhibitor, on the infectivity and proteolytic activity of toxoplasma gondii","volume":"88","author":"Paugam","year":"2002","journal-title":"Parasitol. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106507_b0550","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-7-187","article-title":"Comprehensive study of proteasome inhibitors against plasmodium falciparum laboratory strains and field isolates from gabon","volume":"7","author":"Kreidenweiss","year":"2008","journal-title":"Malar. J."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:43:54Z","timestamp":1758617034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":110,"alternative-id":["S0045206823001670"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106507","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances and future perspectives of noncompetitive proteasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106507"}}